Introduction

This chapter delves into FDA approvals for interchangeable biosimilars, such as Wios and Jubanti for denosumab and a biosimilar of Tocilizumab with IV and sub-Q formulations. It also explores meta-analyses concerning Still's disease, examining the impact of medications on remission rates and steroid usage.